Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (NASDAQ: EPIX) provided an update on its progress and financial results for the second quarter ending March 31, 2021.
Key highlights include promising pharmacokinetic data on EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) and a successful public offering raising approximately $150 million to fund ongoing studies and R&D efforts.
The company reported a net loss of $13 million for the quarter, up from a $9.4 million loss in Q2 2020, with total cash reserves reaching $208.6 million.
ESSA Pharma Inc. (Nasdaq: EPIX) announced a collaboration with Bayer to evaluate EPI-7386, an N-terminal domain androgen receptor inhibitor, in a Phase 1/2 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will assess the efficacy and safety of combining EPI-7386 with Bayer's darolutamide. ESSA will supply EPI-7386 and retains all rights to the drug. The study is set to start in 2021, with EPI-7386 having already received Fast Track designation from the U.S. FDA.
ESSA Pharma Inc. (Nasdaq: EPIX) announced that CEO Dr. David R. Parkinson will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 11:00 AM ET. The presentation will last 30 minutes and include a Q&A session. Dr. Parkinson, COO Peter Virsik, and CFO David S. Wood will also hold one-on-one meetings. Attendees can access the presentation via a webcast on ESSA's website, available for 90 days post-event. The conference aims to update investors on developments within the Canadian healthcare sector.
ESSA Pharma Inc. (Nasdaq: EPIX) presented promising preclinical data for its lead candidate, EPI-7386, at the 2021 AACR Annual Meeting. This investigational drug is a selective inhibitor of the androgen receptor's N-terminal domain, showing high potency and specificity. Key findings include EPI-7386’s capability to inhibit androgen receptor binding to DNA and its effectiveness against various splice variants linked to prostate cancer. The company is currently conducting a Phase 1 clinical trial for metastatic-castration resistant prostate cancer, with further studies planned in collaboration with Janssen and Astellas.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the resignation of Dr. Ari Brettman from its Board of Directors, effective March 26, 2021. Dr. Brettman, a Managing Director at Blackstone's Life Science Group, has been with the Board since 2019. ESSA's Chairman, Richard M. Glickman, expressed gratitude for Dr. Brettman's leadership and insights during his tenure. Dr. Brettman acknowledged the company's growth and highlighted the potential of ESSA's lead candidate, EPI-7386, to transform prostate cancer treatment.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the exercise of an option by underwriters to purchase an additional 724,637 common shares from its recent public offering, bringing total shares issued to 5,555,555 and gross proceeds to approximately $150 million. The offering, which closed on February 22, 2021, will fund clinical activities, including combination studies with EPI-7386 and anti-androgens. Jefferies and Piper Sandler were the joint book-running managers for the offering. Full prospectus details can be found on the SEC and SEDAR websites.
ESSA Pharma Inc. (NASDAQ: EPIX) announced the results of its Annual General Meeting held on February 25, 2021. Shareholders re-elected the board of directors with significant majority support, including David R. Parkinson and Richard M. Glickman, among others. Key approvals included the re-appointment of Davidson & Company LLP as auditors, a new omnibus incentive plan, and amendments to the existing stock option plan. ESSA focuses on developing innovative therapies for prostate cancer, a significant medical area with rising treatment challenges.
ESSA Pharma Inc. (NASDAQ: EPIX) announced that President and CEO Dr. David R. Parkinson will present at three virtual investor conferences in March 2021. The conferences include the Cowen 41st Annual Health Care Conference on March 4 at 12:10 p.m. ET, the H.C. Wainwright Annual Global Life Sciences Conference on March 9 at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 18 at 11:20 a.m. ET. Webcasts will be accessible on the ESSA website and archived for 90 days after each event.
ESSA Pharma Inc. (Nasdaq: EPIX) has announced a clinical collaboration with Astellas Pharma Inc. to evaluate EPI-7386, a novel androgen receptor inhibitor, in combination with enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC). This Phase 1/2 study is set to begin in 2021 and aims to assess the safety, tolerability, and preliminary efficacy of the combination therapy in patients who haven't received second-generation antiandrogens. ESSA retains all rights to EPI-7386, which has received Fast Track designation from the FDA.
ESSA Pharma Inc. (Nasdaq: EPIX) has successfully closed a public offering of 4,830,918 common shares at $27.00 per share, raising approximately $130 million in gross proceeds. The Company has granted underwriters a 30-day option for an additional 724,637 shares. Funds will be allocated toward clinical activities including multiple studies with EPI-7386, a Phase 2 clinical study, and preparatory work for a Phase 3 study. Jefferies and Piper Sandler served as joint book-running managers for this Offering.
